This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profile of Repeat Oral Doses of GSK2140944 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 17, 2012

Primary Completion Date

December 13, 2013

Study Completion Date

December 13, 2013

Conditions

Infections, Respiratory Tract

Interventions

DRUG

GSK2140944

GSK2140944 will be available as immediate release capsules of dose strength 100 mg and 500 mg

DRUG

Placebo

Matching placebo will be available

Trial Locations (1)

GSK Investigational Site, Overland Park